Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study Using WST11 in Patients With Non-Resectable or Inoperable Cholangiocarcinoma

This study has been terminated.
(Early end of enrolment with regards to difficulty met to enrol patients despite previous protocol amendments.)
Sponsor:
Information provided by (Responsible Party):
Steba Biotech S.A.
ClinicalTrials.gov Identifier:
NCT00975039
First received: September 10, 2009
Last updated: July 4, 2012
Last verified: July 2012

September 10, 2009
July 4, 2012
September 2009
June 2011   (final data collection date for primary outcome measure)
Evaluation of the safety based on analysis of adverse events (clinical laboratory tests, electrocardiogram, physical examination, absence of local or general complications and phototoxicity) of WST11 in inoperable or non resectable cholangiocarcinoma [ Time Frame: Patient inclusion - Month 6 ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00975039 on ClinicalTrials.gov Archive Site
  • Evaluation of the antitumor efficacy of WST11-mediated VTP therapy by comparing the objective response rate on the tumor. [ Time Frame: Month 1, Month 3 & Month 6 ] [ Designated as safety issue: No ]
  • Evaluation of the effect of WST11-mediated VTP therapy on cholestasis and on the incidence of biliary complications of obstructive origin. [ Time Frame: Month 1, Month 3 & Month 6 ] [ Designated as safety issue: Yes ]
  • Evaluation of the effect of treatment on patient quality of life QLQ-C30. [ Time Frame: Month 1, Month 3 & Month 6 ] [ Designated as safety issue: No ]
  • Evaluation of the global survival after WST11-mediated VTP [ Time Frame: Month 6 ] [ Designated as safety issue: Yes ]
  • Evaluation of the antitumor efficacy of WST11-mediated VTP therapy by comparing the objective response rate on the tumor. [ Time Frame: Month 1, Month 3 & Month 6 ] [ Designated as safety issue: No ]
  • Evaluation of the effect of WST11-mediated VTP therapy on cholestasis and on the incidence of biliary complications of obstructive origin. [ Time Frame: Month 1, Month 3 & Month 6 ] [ Designated as safety issue: Yes ]
  • Evaluation of the effect of treatment on patient quality of life QLQ-C30. [ Time Frame: Month 1, Month 3 & Month 6 ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Study Using WST11 in Patients With Non-Resectable or Inoperable Cholangiocarcinoma
Evaluation of the Safety and Efficacy of WST11-mediated Vascular Targeted Photodynamic Therapy in Non-resectable or Inoperable Cholangiocarcinoma

The aim of this study is to evaluate the safety of Vascular Targeted Photodynamic therapy with WST11 in patients with non-resectable or inoperable biliary carcinoma.

This is an open-label, prospective, multicentre, phase IIa study, evaluating a new therapeutic agent in the management of patients suffering from inoperable or non resectable biliary carcinoma. The patients will receive the dose of WST11 according to order of inclusion. The first 3 patients will receive 2.5 mg/kg. In the absence of toxicity, the following 9 patients will receive the dose of 5 mg/kg.

The patient is to receive anesthesia. WST11-mediated therapy will consist of the combination of single IV administration of WST11 at doses of 2.5mg/kg or 5mg/kg, using 753nm laser light at a fixed power of (150mW/cm) and light energy (200 J/cm) delivered through a diffusing fiber. The fiber is introduced in a transparent standard ERCP catheter and positioned under radioscopy in front of the lesion.

Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Cholangiocarcinoma
Drug: WST11
WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 2.5 and 5 mg/kg, using 753nm laser light at a fixed power (150 mW/cm) and light energy (200 J/cm). Illumination in the bile duct is performed by inserting a diffusing fiber, with cylindrical uniform light distribution, in a transparent standard ERCP catheter and by positioning, under radioscopy, the illumination tip of the diffusing fiber in front of the lesion.
Other Name: WST11-mediated VTP
Experimental: WST11
Treatment with WST11-mediated VTP
Intervention: Drug: WST11
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
7
September 2012
June 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient having signed the consent form to take part in the study
  • Patient aged over 18 years, with no upper age limit
  • Patient with histologically proven cholangiocarcinoma
  • Patient with cholangiocarcinoma, inoperable or non resectable owing to extension, age or concomitant diseases
  • Bilirubin level decrease of more than 50% after stent insertion compared to base level
  • Patient with a WHO Performance Scale ≤ 2
  • Patient in whom efficient drainage is performed by means of a plastic biliary stent endoscopically or radiologically
  • Patient capable of completing the quality of life questionnaires
  • Women of child-bearing potential must have a negative pregnancy test, and must thereafter prove to be using acceptable contraception (oral contraceptive pill, hormone patches, or IUD)

Exclusion Criteria:

  • Absence of consent to take part in the study
  • Patient with operable biliary carcinoma
  • Class ASA IV patients
  • Patients presenting clinical and laboratory signs of biliary infection
  • Absence of bilirubin decrease after stent insertion
  • Patients with extrinsic biliary compression
  • Patients already having received or currently receiving radiotherapy or chemotherapy for cholangiocarcinoma or needing to be treated during the first month of the follow-up
  • Known metastatic lesions
  • Patients having received immediate treatment by insertion of a metal stent
  • Patients with porphyria or known hypersensitivity to porphyrins (contraindication to WST11)
  • Patient receiving prohibited treatment at the time of inclusion in the study
  • Pregnant or breast-feeding women
  • Non-menopausal women not using effective contraception
  • Majors under protection as per the French Public Health Code
  • Persons not registered with or covered by a social security system
  • Persons in an exclusion period relative to other biomedical study
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
France
 
NCT00975039
CLIN904 CCM201
No
Steba Biotech S.A.
Steba Biotech S.A.
Not Provided
Principal Investigator: Emmanuel Ben Soussan, MD Clinique de l'Alma
Steba Biotech S.A.
July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP